[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587437":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":34,"locations":35,"responsibleParty":59,"collaborators":63,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":34,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":34,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":34,"overallStatus":37,"whyStopped":34,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Combined With CACAG Regimen","EXPERIMENTAL","The CACAG+Venetoclax regimen has a total treatment period of 1 week, with a treatment cycle every 4 weeks, and a total of 1 course of treatment.\n\nChidamide: 30 mg, twice a week, for a total of 2 administrations; Azacitidine: 75 mg\u002Fm\\^2 from day 1 to day 7; Cytarabine (Ara-C): 75-100 mg\u002Fm\\^2 every 12 hours from day 1 to day 7; Aclarubicin: 20 mg\u002Fm\\^2 on days 1, 3, and 5; Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg\u002Fday, continued until neutrophil recovery and white blood cell count is ≥20,000\u002FμL; Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg from day 3 to day 14, when used in combination with azole drugs, the dosage is reduced to 100 mg\u002Fday.",[13],"Drug: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor",{"label":15,"type":16,"description":17,"interventionNames":18},"\"3+7\" Regimen","ACTIVE_COMPARATOR","Idarubicin+cytarabine(IA) regimen or daunorubicin+cytarabine(DA) regimen for newly diagnosed AML.Recipients were randomized and those entering this group received IA or DA induction chemotherapy. With the IA regimen,recipients received idarubicin(8-10 mg\u002Fm2) for three days and cytarabine(75-100 mg\u002Fm2, every 12 hrs) for seven days. With the DA regimen,recipients received daunorubicin(60 mg\u002Fm2)for three days and cytarabine(75-100 mg\u002Fm2,every 12 hrs)for seven days.",[19],"Drug: \"3+7\"",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor","Azacytidine (75 mg\u002Fm2\u002Fday, days 1 to 7). Cytarabine (75-100 mg\u002Fm2 bid, days 1 to 5). Aclacinomycin(20 mg\u002Fday, days 1,3,5). Chidamide (30 mg\u002Fday , days 1,4,8,11). Venetoclax (400 mg\u002Fday, days 1 to 14,Combined with posaconazole reduced to 100 mg\u002Fday,Combined with voriconazole reduced to 200 mg\u002Fday ).\n\nGranulocyte colony-stimulating factor (300 μg\u002Fday, day 0 until agranulocytosis recovery)",[9],[27],"CACAG+VEN",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"\"3+7\"","IA regimen:\n\nIdarubicin (8-10 mg\u002Fm2) for 3 days . Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.\n\nDA regimen:\n\nDaunorubicin(60 mg\u002Fm2) for 3 days. Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.",[15],[33],"IA or DA",null,[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,55],{"name":51,"role":52,"phone":53,"phoneExt":34,"email":54},"Daihong Liu, doctor","CONTACT","86-13681171597","daihongrm@163.com",{"name":56,"role":52,"phone":57,"phoneExt":34,"email":58},"Qingyang Liu, doctor","+8617808071170","1074745197@qq.com",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Daihong Liu","Director of the Department of Hematology",[64,66,68,70,72,74],{"name":65,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":67,"class":6},"Yantai Yuhuangding Hospital",{"name":69,"class":6},"The General Hospital of Western Theater Command",{"name":71,"class":6},"940 Hospital of the People's Liberation Army Joint Logistic Support Force",{"name":73,"class":6},"960th Hospital of Joint Logistics Support Force of People's Liberation Army of China",{"name":75,"class":6},"Jining First People's Hospital","100587437","phase-2-a-multicenter-rct-of-37-vs-venetoclax--cacag-in-newly-diagnosed-midhigh-risk-aml-patients-100587437",false,"NCT06928376","A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid\u002FHigh-Risk AML Patients","A Multicenter, Prospective, Randomized Controlled Study of the Standard \"3+7\" Regimen Versus Venetoclax Combined With CACAG Regimen in Newly Diagnosed Adult Patients With Intermediate- and High-risk Acute Myeloid Leukemia","Inclusion Criteria:\n\nAge 14 to 75 years (no gender limitation) Newly diagnosed with intermediate- or high-risk AML (excluding M3) Liver function: ALT and AST ≤ 2.5 times upper limit of normal; bilirubin ≤ 2 times upper limit of normal Renal function: creatinine ≤ upper limit of normal No uncontrolled infections, organ dysfunction, or severe mental illness ECOG performance status score of 0-2 and predicted survival ≥ 4 months No severe allergic constitution\n\nExclusion Criteria:\n\nAllergy or contraindication to the study drug Pregnant or breastfeeding female patients Known history of alcohol or drug addiction (due to potential non-compliance) Mental illness or conditions preventing protocol compliance Less than 6 weeks after major organ surgery Liver function: ALT and AST \\> 2.5 times upper limit of normal; bilirubin \\> 2 times upper limit of normal Renal function: creatinine \\> upper limit of normal Deemed unsuitable for the clinical trial (poor compliance, substance abuse, etc.)\n\n\\-","ALL","14 Years","75 Years",{"count":87,"type":88},160,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional \"3+7\" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).",[94,95],"Acute Myeloid Leukemia","First Line Therapy","2026-05-04",{"date":98,"type":99},"2026-05-08","ACTUAL",{"date":101,"type":99},"2024-04-18",{"date":103,"type":88},"2026-09-01",{"name":5,"class":6},1]